CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer

Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 10(6) cells were...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Changsong, Xie, Tong, Zhou, Jun, Wang, Xicheng, Gong, Jifang, Zhang, Xiaotian, Li, Jian, Yuan, Jiajia, Liu, Chang, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492318/
https://www.ncbi.nlm.nih.gov/pubmed/37689733
http://dx.doi.org/10.1186/s13045-023-01491-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492318/
https://www.ncbi.nlm.nih.gov/pubmed/37689733
http://dx.doi.org/10.1186/s13045-023-01491-9

Ejemplares similares